CARbon monoxidE intoxiCatiOn in Korea: Prospective Cohort (CARE CO Cohort)
Carbon Monoxide Poisoning · Myocardial Injury · Neurologic Deficits · Image, Body · Therapy · Prognostic Factors · Complications
De qué trata este estudio
El registro indica que este estudio recluta participantes. La disponibilidad puede variar por centro.
- Tipo de estudio
- Observacional
- Fase
- No aplica / no indicada
- Rango de edad
- No especificado - No especificado
- Sexo admitido
- Todos los sexos
- Voluntarios sanos
- No aceptados
- Participantes
- 1500 Estimado
Estos son puntos de partida, no una decisión de elegibilidad. El equipo debe revisar todos los requisitos.
Las explicaciones y la navegación están en español. Los textos proporcionados por el registro, incluidos títulos, resúmenes y criterios, se conservan en su idioma original. Puedes pedir orientación en español a WCR.
Acerca de la investigación
This prospective cohort study enrolls subjects who experience carbon monoxide (CO) poisoning. The purpose of the study is to evaluate therapeutic effects of various treatments and short and long-term outcomes in CO poisoned patients. In addition, complications of brain and heart susceptible to CO are investigated through various ways and the association between complications and the patient's prognosis is also investigated. All subjects will be regularly monitored by physicians participating in this study.
Leer la descripción completa
This prospective cohort study enrolls subjects who experience CO poisoning. The purpose of the study is to evaluate therapeutic effects of various treatments, including hyperbaric oxygen therapy (HBO), therapeutic hypothermia (TH), and additional drugs, and short and long-term outcomes, such as neurocognitive sequelae or mortality, in CO poisoned patients. In addition, complications of brain and heart susceptible to CO are investigated through a variety of ways, such as magnetic resonance image (MRI), computed tomography (CT), ultrasound, and laboratory test, and the association between various complications and the patient's prognosis is also investigated. All subjects will be regularly monitored by physicians participating in this study.
¿Quién podría participar?
La lista siguiente contiene el texto del patrocinador. Puede incluir condiciones, tratamientos previos, resultados de pruebas y otros requisitos. Aparecer en tu búsqueda no significa que califiques.
Inclusion Criteria:
- Acute CO poisoning
Exclusion Criteria:
- Declined to enrollment in the study
Población del estudio
Acute CO poisoning
Entiende la evaluación inicialTratamiento, grupos y participación
El registro puede describir tratamientos y duración sin incluir un calendario completo. Pide al equipo las visitas, procedimientos, riesgos, costos y alternativas. Mantén tu atención habitual salvo que tu médico te indique un cambio.
- Asignación
- No informado
- Enmascaramiento
- No informado
Acute CO poisoning
A diagnosis of CO poisoning is made according to medical history and carboxyhemoglobin \>5% (\>10% in smokers).
Diagnostic Test: Cardiac MRI · Procedure: Hyperbaric oxygen therapy
Cardiac MRI DIAGNOSTIC_TEST
1. Cardiac MRI be taken to CO poisoned patients
2. Cardiac CT be taken to CO poisoned patients
3. TTE be taken to CO poisoned patients
4. Brain MRI be taken to CO poisoned patients
5. Neurocognitive function tests be taken to CO poisoned patients
6. Laboratory tests be taken to CO poisoned patients
Hyperbaric oxygen therapy PROCEDURE
1. Hyperbaric oxygen therapy be used for CO poisoned patients
2. Therapeutic hypothermia be used for CO poisoned patients
Qué evalúan los investigadores
Estas medidas indican qué se estudia. No prueban que un tratamiento funcione.
Medidas principales
Therapeutic response to HBO at 1 month
Plazo: At 1 month after CO exposure
Therapeutic response to HBO according to times from rescue to first HBO and frequency and pressure of HBO at 1 month after CO exposure
Therapeutic response to HBO at 6 months
Plazo: At 6 months after CO exposure
Therapeutic response to HBO according to times from rescue to first HBO and frequency and pressure of HBO at 6 months after CO exposure
Predictors and model development for participants with poor outcome including mortality, and neurocognitive and psychological sequelae at 1 month after CO exposure evaluated by such as neurocognitive function tests
Plazo: Within 1 month after CO exposure
Predictors and model development for poor outcome including mortality, and neurocognitive and psychological sequelae at 1 month after CO exposure evaluated by tools, such as global deterioration scale (GDS) or Carbon Monoxide Neuropsychological Screening Battery (CONSB), etc, through variables, such as clinical features, laboratory tests, or imaging study that can be investigated within 1 month
Predictors and model development for participants with poor outcome including mortality, and neurocognitive and psychological sequelae at 6 months after CO exposure evaluated by such as neurocognitive function tests
Plazo: Within 1 month after CO exposure
Predictors and model development for poor outcome including mortality, and neurocognitive and psychological sequelae at 6 months after CO exposure evaluated by tools, such as global deterioration scale (GDS) or Carbon Monoxide Neuropsychological Screening Battery (CONSB), etc, through variables, such as clinical features, laboratory tests, or imaging study that can be investigated within 1 month
Predictors and model development for participants with poor outcome including mortality, and neurocognitive and psychological sequelae at 12 months after CO exposure evaluated by such as neurocognitive function tests
Plazo: Within 1 month after CO exposure
Predictors and model development for poor outcome including mortality, and neurocognitive and psychological sequelae at 12 months after CO exposure evaluated by tools, such as global deterioration scale (GDS) or Carbon Monoxide Neuropsychological Screening Battery (CONSB), etc, through variables, such as clinical features, laboratory tests, or imaging study that can be investigated within 1 month
Medidas secundarias
Therapeutic response to HBO at 12 months
Plazo: At 12 months after CO exposure
Therapeutic response to HBO according to times from rescue to first HBO and frequency and pressure of HBO at 12 months after CO exposure
Therapeutic response to TH combined with HBO at 1 month
Plazo: At 1 month after CO exposure
Therapeutic response to TH combined with HBO in acute severe CO poisoning at 1 month after CO exposure
Therapeutic response to TH combined with HBO at 6 months
Plazo: At 6 months after CO exposure
Therapeutic response to TH combined with HBO in acute severe CO poisoning at 6 months after CO exposure
Therapeutic response to TH combined with HBO at 12 months
Plazo: At 12 months after CO exposure
Therapeutic response to TH combined with HBO in acute severe CO poisoning at 12 months after CO exposure
Therapeutic response to HBO according to presence of apolipoprotein E4 at 1 month
Plazo: At 1 month after CO exposure
Therapeutic response to HBO according to presence of apolipoprotein E4 genotype at 1 month after CO exposure
Therapeutic response to HBO according to presence of apolipoprotein E4 at 6 months
Plazo: At 6 months after CO exposure
Therapeutic response to HBO according to presence of apolipoprotein E4 genotype at 6 months after CO exposure
Therapeutic response to HBO according to presence of apolipoprotein E4 at 12 months after CO exposure
Plazo: At 12 months after CO exposure
Therapeutic response to HBO according to presence of apolipoprotein E4 genotype at 12 months after CO exposure
Cardiac injury evaluated by cardiac MRI in acute phase
Plazo: Within 1 month after CO exposure
Cardiac injury related to CO poisoning evaluated by cardiac MRI in acute phase
Cardiac injury evaluated by cardiac MRI in chronic phase
Plazo: Follow-up cardiac MRI (at 4-8 months after CO exposure)
Cardiac injury related to CO poisoning evaluated by cardiac MRI in chronic phase
Cardiac injury evaluated by cardiac CT
Plazo: Within 1 month after CO exposure
Cardiac injury evaluated by cardiac CT in CO poisoning
Cardiac injury evaluated by TTE in acute phase
Plazo: Within 14 days after CO exposure
Cardiac injury related to CO poisoning evaluated by TTE in acute phase
Cardiac injury evaluated by TTE in chronic phase
Plazo: Within 4-8 months after CO exposure
Cardiac injury related to CO poisoning evaluated by TTE in chronic phase
Brain injury evaluated by brain imaging modality related to CO poisoning
Plazo: Within 6 months after CO exposure
Brain injury evaluated by brain MRI in CO poisoning
Brain injury related to CO poisoning
Plazo: Within 6 months after CO exposure
Brain injury evaluated by laboratory tests in CO poisoning
Association between presence of cardiac injury, which is evaluated by cardiac enzyme or cardiac imaging studies, and poor outcome including mortality, and neurocognitive and psychological sequelae at 1 month after CO exposure
Plazo: Outcomes at 1 month after CO exposure
Association between presence of cardiac injury, which is evaluated by electrocardiogram, cardiac enzyme, or cardiac imaging studies, and poor outcome including mortality, and neurocognitive and psychological sequelae at 1 month after CO exposure
Association between presence of cardiac injury, which is evaluated by cardiac enzyme or cardiac imaging studies, and poor outcome including mortality, and neurocognitive and psychological sequelae at 6 months after CO exposure
Plazo: Outcomes at 6 months after CO exposure
Association between presence of cardiac injury, which is evaluated by electrocardiogram, cardiac enzyme, or cardiac imaging studies, and poor outcome including mortality, and neurocognitive and psychological sequelae at 6 months after CO exposure
Association between presence of cardiac injury, which is evaluated by cardiac enzyme or cardiac imaging studies, and poor outcome including mortality, and neurocognitive and psychological sequelae at 12 months after CO exposure
Plazo: Outcomes at 12 months after CO exposure
Association between presence of cardiac injury, which is evaluated by electrocardiogram, cardiac enzyme, or cardiac imaging studies, and poor outcome including mortality, and neurocognitive and psychological sequelae at 12 months after CO exposure
Association between presence of cardiac injury, which is evaluated by cardiac enzyme or cardiac imaging studies, and poor outcome including mortality, and neurocognitive and psychological sequelae at 5 years after CO exposure
Plazo: Outcomes at 5 years after CO exposure
Association between presence of cardiac injury, which is evaluated by electrocardiogram, cardiac enzyme, or cardiac imaging studies, and poor outcome including mortality, and neurocognitive and psychological sequelae at 5 years after CO exposure
Association between presence of brain injury, which is evaluated by brain imaging studies, and poor outcome including mortality, and neurocognitive and psychological sequelae at 1 month after CO exposure evaluated by neurocognitive function tests
Plazo: Outcomes at 1 month after CO exposure
Association between presence of brain injury, which is evaluated by brain MRI, etc, and poor outcome including mortality, and neurocognitive and psychological sequelae at 1 month after CO exposure evaluated by such as GDS or CONSB, etc
Association between presence of brain injury, which is evaluated by brain imaging studies, and poor outcome including mortality, and neurocognitive and psychological sequelae at 6 months after CO exposure evaluated by neurocognitive function tests
Plazo: Outcomes at 6 months after CO exposure
Association between presence of brain injury, which is evaluated by brain MRI, etc, and poor outcome including mortality, and neurocognitive and psychological sequelae at 6 months after CO exposure evaluated by such as GDS or CONSB, etc
Association between presence of brain injury, which is evaluated by brain imaging studies, and poor outcome including mortality, and neurocognitive and psychological sequelae at 12 months after CO exposure evaluated by neurocognitive function tests
Plazo: Outcomes at 12 months after CO exposure
Association between presence of brain injury, which is evaluated by brain MRI, etc, and poor outcome including mortality, and neurocognitive and psychological sequelae at 12 months after CO exposure evaluated by such as GDS or CONSB, etc
Association between presence of brain injury, which is evaluated by brain imaging studies, and poor outcome including mortality, and neurocognitive and psychological sequelae at 5 years after CO exposure evaluated by neurocognitive function tests
Plazo: Outcomes at 5 years after CO exposure
Association between presence of brain injury, which is evaluated by brain MRI, etc, and poor outcome including mortality, and neurocognitive and psychological sequelae at 5 years after CO exposure evaluated by such as GDS or CONSB, etc
Association between presence of brain injury, which is evaluated by laboratory tests, and poor outcome including mortality, and neurocognitive and psychological sequelae at 1 month after CO exposure evaluated by neurocognitive function tests
Plazo: Outcomes at 1 month after CO exposure
Association between presence of brain injury, which is evaluated by laboratory tests, etc, and poor outcome including mortality, and neurocognitive and psychological sequelae at 1 month after CO exposure evaluated by such as GDS or CONSB, etc
Association between presence of brain injury, which is evaluated by laboratory tests, and poor outcome including mortality, and neurocognitive and psychological sequelae at 6 months after CO exposure evaluated by neurocognitive function tests
Plazo: Outcomes at 6 months after CO exposure
Association between presence of brain injury, which is evaluated by laboratory tests, etc, and poor outcome including mortality, and neurocognitive and psychological sequelae at 6 months after CO exposure evaluated by such as GDS or CONSB, etc
Association between presence of brain injury, which is evaluated by laboratory tests, and poor outcome including mortality, and neurocognitive and psychological sequelae at 12 months after CO exposure evaluated by neurocognitive function tests
Plazo: Outcomes at 12 months after CO exposure
Association between presence of brain injury, which is evaluated by laboratory tests, etc, and poor outcome including mortality, and neurocognitive and psychological sequelae at 12 months after CO exposure evaluated by such as GDS or CONSB, etc
Association between presence of brain injury, which is evaluated by laboratory tests, and poor outcome including mortality, and neurocognitive and psychological sequelae at 5 years after CO exposure evaluated by neurocognitive function tests
Plazo: Outcomes at 5 years after CO exposure
Association between presence of brain injury, which is evaluated by laboratory tests, etc, and poor outcome including mortality, and neurocognitive and psychological sequelae at 5 years after CO exposure evaluated by such as GDS or CONSB, etc
Therapeutic response to drugs at 1 month
Plazo: At 1 month after CO exposure
Therapeutic response to additional drug including steroid at 1 month after CO exposure
Therapeutic response to drugs at 6 months
Plazo: At 6 months after CO exposure
Therapeutic response to additional drug including steroid at 6 months after CO exposure
Therapeutic response to drugs at 12 months
Plazo: At 12 months after CO exposure
Therapeutic response to additional drug including steroid at 12 months after CO exposure
Prevalence of poor outcomes including mortality, and neurocognitive and psychological sequelae after CO poisoning at 1 month
Plazo: At 1 month after CO exposure
Prevalence of poor outcomes including mortality, and neurocognitive and psychological sequelae evaluated by, such as GDS or CONSB, etc, after CO poisoning at 1 month after CO exposure
Prevalence of poor outcomes including mortality, and neurocognitive and psychological sequelae after CO poisoning at 6 months
Plazo: At 6 months after CO exposure
Prevalence of poor outcomes including mortality, and neurocognitive and psychological sequelae evaluated by, such as GDS or CONSB, etc, after CO poisoning at 6 months after CO exposure
Prevalence of poor outcomes including mortality, and neurocognitive and psychological sequelae after CO poisoning at 12 months
Plazo: At 12 months after CO exposure
Prevalence of poor outcomes including mortality, and neurocognitive and psychological sequelae evaluated by, such as GDS or CONSB, etc, after CO poisoning at 12 months after CO exposure
Prevalence of poor outcomes including mortality, and neurocognitive and psychological sequelae after CO poisoning at 5 years
Plazo: At 5 years after CO exposure
Prevalence of poor outcomes including mortality, and neurocognitive and psychological sequelae evaluated by, such as GDS or CONSB, etc, after CO poisoning at 5 years after CO exposure
Organ injury related to CO poisoning
Plazo: Within 6 months after CO exposure
Organ injury, such as lung, kidney, liver, pancreas, or bowel, etc, related to CO poisoning
Complications related to CO poisoning
Plazo: Within 6 months after CO exposure
Complications, such as pulmonary thromboembolism or rhabdomyolysis, etc, related to CO poisoning
Effect of HBO for delayed neurocognitive and psychological dysfunction at 1 year after onset
Plazo: Within 1 year after delayed neurocognitive and psychological sequelae onset
Effect of HBO for patient with delayed neurocognitive and psychological sequelae at 1 year after sequelae onset
Effect of HBO for delayed neurocognitive and psychological dysfunction at 2 years after onset
Plazo: Within 2 years after delayed neurocognitive and psychological sequelae onset
Effect of HBO for patient with delayed neurocognitive and psychological sequelae at 2 years after sequelae onset
Validation of methods evaluating neurocognitive and psychological outcomes
Plazo: Within 6 months after CO exposure
Validation of methods evaluating neurocognitive and psychological outcomes within 6 months
Revisa las tablas completas y sus limitaciones en el registro oficial.
Abrir resultados oficiales ↗Centros de investigación (1)
El estado general puede diferir del estado de un centro. Confirma la disponibilidad antes de trasladarte.
1 centros
Wonju Severance Christian HospitalWŏnju, Gangwon-do, South KoreaReclutando
Equipo y fechas
- Patrocinador principal
- Wonju Severance Christian Hospital
- Inicio del estudio
- 29 jul 2020 Real
- Finalización primaria
- 2030-12 Estimado
- Finalización del estudio
- 2035-12 Estimado
- Primera publicación
- 29 jul 2020 Real
- Última actualización
- 10 nov 2026 Real
Contactos oficiales del estudio
Título oficial del estudio
CARbon monoxidE intoxiCatiOn in Korea: Prospective Cohort (CARE CO Cohort)
Consulta a Wellness Clinical Research
Tu mensaje va a WCR, incluso si otra organización realiza este estudio. WCR puede orientarte, pero podría no realizar este estudio, tener acceso a su equipo ni poder inscribirte.
Fuente: API v2 de ClinicalTrials.gov. Patrocinadores e investigadores envían la información. La NLM no aprueba la seguridad ni la ciencia de todos los estudios registrados. Aviso del registro.
Consultado: 12 nov 2026 · Última actualización del registro: 10 nov 2026